The Lumixyl Topical Brightening System made it’s debut at the German Society for Aesthetic Botulinum Toxin Therapy in Frankfurt last week. The products were received as an exciting new alternative to hydroquinone, given the continued scrutiny that hydroquinone has been under throughout Europe.
Advanced Bio-Technologies Deutschland GmbH (ABT) is handling all of the marketing, distribution and sales activity for the Lumixyl brand throughout Germany and Austria, in Coordination with international master-distributor Zaina Pharma.
“We are thrilled to have such capable partners in ABT and Zaina for the these key European markets,” said Curtis Cluff, CEO of Envy Medical, Inc., the makers of the Lumixyl Topical Brightening System. “They really understand the Lumixyl technology and developed strong relationships for the brand among the key opinion leaders of the Germain Aesthetic Medicine and Dermatology associations.”
In fact, several of these thought leaders have announced plans to undertake their own clinical studies using patients of european and germanic background, the ongoing results of which will be published in the coming months.
Lumixyl is based on a peptide technology developed by Stanford University researchers and dermatologists. It is the first in a class of peptides licensed from Stanford by Envy Medical, Inc., discovered to inhibit tyrosinase, the enzyme responsible for melanin synthesis. In fact studies published in the Journal of Investigative Dermatology and the the Journal of Drugs in Dermatology show that it is more potent in restraining tyrosinase than hydroquinone, and yet it is non-toxic, and non-irritating to the skin. That combination of features has put this technology in high demand around the world, as patients look for better ways to brighten their skin and to safely diminish the appearance of dark patches on their skin (dyschromia) without the redness and excessive peeling they often experience with traditional topical applications.
The Lumixyl System contains four unique product formulations that are designed to synergistically work together. This includes 1) Active-Prep – a low pH antioxidant cleanser, 2) Brightening Creme – with Stanford developed decapeptide-12, 3) GlycoPeel 20 Rapid Exfoliating Lotion, and 4) MoistureLock Sunscreen SPF30, with Lumiblock technology for elegant broad spectrum UV protection. When used together, the skin is aided in its ability to look and act younger and healthier, and to break up those dark patches of skin that are caused by aging, photo-damage, acne and/or other environmental and hormonal factors.
About ABT Deutschland and Zaina Pharma. For more information on where you can find the Lumixyl Topical Brightening System in Germany and Austria, go to www.abt-derma.de. Information on Zaina Pharma Inc., can be found at www.zainapharma.com.
About Lumixyl. Lumixyl is manufactured and marketed by Envy Medical, Inc. headquartered in Westlake Village, California. Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion™ for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available in a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com or by calling (888) 848-3633.
For media inquiries or to secure expert testimonial please contact Melissa Kelz, Principal, Melissa Kelz PR at firstname.lastname@example.org (312) 543-8300